InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways
September 09, 2020 08:10 ET
|
InveniAI
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...
Tackling Tuberculosis with AI: Novel TBMeld® Platform to Transform Research in the Prevention and Treatment of Tuberculosis
July 31, 2020 08:00 ET
|
InveniAI
-InveniAI announces partnership with the Mueller Health Foundation (MHF) to create a first of its kind AI-driven platform to be used for the discovery, tracking, and evaluation of 1) novel TB...
InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare
July 29, 2020 08:30 ET
|
InveniAI
Three-year strategic collaboration to leverage InveniAI’s AI- and ML-powered Platform, AlphaMeld® after a successful proof-of-value collaborationAlphaMeld® will capture consumer-specific innovation...
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
June 02, 2020 08:00 ET
|
InveniAI
GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across...
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite
November 06, 2019 08:00 ET
|
InveniAI
GUILFORD, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
InveniAI Launches Suite of Products Powered by AlphaMeld™, an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences
September 17, 2019 08:30 ET
|
InveniAI
- CIMeld™, an AlphaMeld™ powered product for competitive/business intelligence, is set to launch at PharmaCI USA 2019 - Tailored suite of products to address high value questions accelerating...
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU
July 02, 2019 08:31 ET
|
InveniAI
Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI establishes presence in Basel, Switzerland...
InveniAI to be Featured at the 2019 BIO International Convention
May 29, 2019 08:32 ET
|
InveniAI
GUILFORD, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
Microsoft Features InveniAI in their Series, NowThis Future: "AI for Change"
March 26, 2019 07:30 ET
|
InveniAI
GUILFORD, Conn., March 26, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform...
InveniAI Featured in The Guardian’s Rare Disease Campaign to Showcase how Artificial Intelligence can be Leveraged to Create Patient Solutions
March 01, 2019 09:00 ET
|
InveniAI
GUILFORD, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform...